One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient

Transplant International

Volumn 18, Issue 1, 2005, Pages 36-42

  Montini, Giovanni ^a,f   Murer, Luisa ^a   Ghio, Luciana ^b   Pietrobon, Beatrice ^a   Ginevri, Fabrizio ^c   Ferraresso, Mariano ^d   Cardillo, Massimo ^d   Scalamogna, Mario ^d   Perfumo, Francesco ^c   Edefonti, Alberto ^b   Zanon, Giovanni Franco ^e   Zacchello, Graziella ^a  

^a Pediatric Department   (Italy)

^b Nephrology Division   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e Pediatric Surgical Unit   (Italy)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Acute rejection; Banff classification; Basiliximab; Children; Kidney transplantation; Mycophenolate mofetil; Renal transplantation; Routine biopsies; Steroid withdrawal; Tacrolimus

Indexed keywords

BASILIXIMAB; CELL CEPT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; CORTICOSTEROID; DRUG DERIVATIVE; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; VIRUS INFECTION; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; BIOPSY; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TACROLIMUS;

EID: 21644483598     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.00003.x     Document Type: Article

References (25)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantaion. N Engl J Med 2002; 346: 580.
2. Benfield MR, McDonald RA, Bartosh S, Ho PL, Harmon W. Changing trends in pediatric transplantation: 2001 annual report of the American pediatric renal transplant cooperative study. Pediatr Transplant 2003; 7: 321.
3. Tejani A, Leung Ho P, Emmett L, Stablein DM. Reduction in acute rejections decreases chronic rejection graft failure in children; a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002; 2: 142.
4. Tonshoff B, Mehls O. Factors affecting growth and strategies for treatment in children after renal transplantation. Pediatr Transplant 1997; 1: 176.
5. Bartoszek M, Szefler SJ. Corticosteroid therapy in adolescent patients. J Adolesc Health Care 1987; 8: 84.
6. Lerut JP. Avoiding steroids in solid organ transplantation. Transpl Int 2003; 16: 213.
7. Moons P, Vanrenterghem Y, van Hoff JP, et al. Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen. Transplant Proc 2002; 34: 1691.
8. Hillbrands LB, Hoitsma AJ, Koene RA. The effect of immunosuppressive drugs on quality of life after renal transplantation. Transplantation 1995; 59: 1263.
9. Reisman L, Lieberman KV, Burrows L, Schanzer H. Follow-up of cysclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49: 76.
10. Roberti I, Reisman L, Lieberman KV, Burrows L. Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). Clin Transplant 1994; 8: 405.
11. Ghio L, Tarantino A, Edefonti A, et al. Advantages of cycloporine as sole immunosuppressive agent in children with transplanted kidneys. Transplantation 1992; 54: 834.
12. Aikawa A, Miyagi M, Motoyama O, et al. Pathological evaluation of steroid withdrawal in pediatric renal transplant recipients. Pediatr Transplant 1999; 3: 131.
13. Ellis D. Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants. Pediatr Nephrol 2000; 14: 689.
14. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13.
15. Racusen L, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
16. Schwartz GJ, Haycock GB, Edelman CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259.
17. Fusaro F, Murer L, Busolo F, Rigamonti F, Zanon GF, Zacchello G. CMV and BK ureteritis: which prognosis for the renal graft? J Nephr 2003; 16: 591.
18. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141.
19. Garcia CD, Schneider L, Barros VR, et al. Pediatric renal transplantation under tacrolimus or cyclosporine immunosuppression and basiliximab induction. Transplant Proc 2002; 34: 2533.
20. Pape L, Henne T, Strehlau J, et al. Long term stable glomerular filtration rate achieved with tacrolimus in pediatric renal transplantation. Transplant Proc 2002; 34: 2211.
21. Wlodarczyk Z, Walaszewski J, Perner F. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus treated kidney transplant recipient. Ann Transplant 2002; 7: 28.
22. Squifflet JP, Vanrenterghem Y, van Hooff JP, et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34: 1584.
23. Swiatecka-Urban A, Garcia C, Feuerstein D, et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephr 2001; 16: 693.
24. Ustinov J, Loginov R, Bruggeman C, Suni J, Hayry P, Lautenschlager I. CMV-induced class II antigen expression in various rat organs. Transpl Int 1994; 7: 302.
25. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause and effect relationship? Lancet Infet Dis 2002; 2: 539.